

5412/1E887US2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Bruce H. Morimoto, et al.

Serial No: Not Available

Filed: Concurrently

EXPRESS MAIL CERTIFICATE

Date 7-24-01 Loc EL903058707 WS

I hereby certify that, on the date indicated above, this paper or fee was deposited with the U.S. Postal Service & that it was addressed for delivery to the Assistant Commissioner for Patents, Washington, DC 20231 by "Express Mail Post Office to Addressee" service.

G. KARASZI J. Karaszi
Name (Print) Signature

(U.S. National Phase of PCT/US00/04140 filed 16 February 2000)

For: Phosphocholine Linked Prodrug Derivatives

**Honorable Commissioner of
Patents and Trademarks
Washington, D.C. 20231**

INFORMATION DISCLOSURE STATEMENT

Sir:

In order to comply with discretionary regulations 37 CFR 1.97 and 1.98, attached hereto is Form PTO-1449, and copies¹ of the documents listed thereon. These documents contain information which the Examiner may consider to be important in deciding whether to allow the present application to issue as a patent.

¹To the extent that a document is listed and no copy of same is attached, then such document is not at the present time available to the undersigned or is available in the file of a parent application. If a listed document is not in the English language and an English translation is readily available, such translation is also attached; if translation is not attached it is not readily available to the undersigned. If a foreign language patent document is cited, and an English language equivalent is known to the undersigned, then such equivalent patent is also cited on the attached form along with the corresponding foreign language patent and a connecting arrow indicated therebetween; if no such English language equivalent is cited, then none is known to the undersigned.


The present Disclosure Statement is being submitted to bring to the Examiner's attention the International Search Report dated June 9, 2000 and the references cited therein in applicant's counterpart International patent application. Copies of the Search Report and references cited therein are enclosed herewith.

In accordance with MPEP Sections 609 and 707.05(b), it is requested that each document cited (including any cited in applicant's specification which is not repeated on the attached Form PTO-1449) be given thorough consideration and that it be cited of record in the prosecution history of the present application by initialing on Form PTO-1449. Such initialing is requested even if the Examiner does not consider a cited document to be sufficiently pertinent to use in a rejection, or otherwise does not consider it to be prior art for any reason, or even if the Examiner does not believe that the guidelines for citation have been fully complied with. This is requested so that each document becomes listed on the face of the patent issuing on the present application.

The present Disclosure Statement is being submitted in compliance with 37 CFR 1.56 insofar as an Examiner might consider any of the cited documents important in deciding whether to allow the application to issue as a patent, but the citation of each document is not to be construed as an admission that such document is necessarily relevant or prior art. No representation is intended that the cited documents represent the results of a complete search, and it is anticipated that the Examiner, in the normal course of examination, will make an independent search and will determine the best prior art consistent with 37 CFR 1.104(a) and 1.106(b) and, in the course of each search, will review for relevance every document cited on the attached form even if not initialed.

Early and favorable consideration is earnestly solicited.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Howard M. Frankfort", written over a horizontal line.

Howard M. Frankfort
Registration No. 32,613
Agent for Applicant(s)

DARBY & DARBY P.C.
805 Third Avenue
New York, N.Y. 10022
(212) 527-7700